MethylGene

MethylGene is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics primarily targeting cancer. Founded in 1997, it trades on the public market under the symbol TSX:MYG. The company's product portfolio includes MGCD265, an oral, multi-targeted kinase inhibitor currently in various clinical trials for cancer treatment. Another candidate, MGCD290, is a fungal Hos2 inhibitor intended for use with fluconazole for severe fungal infections and has successfully completed Phase I clinical studies. Mocetinostat (MGCD0103), an oral, isoform-selective HDAC inhibitor, has shown promise in numerous Phase II trials for cancer, currently undergoing a Phase II trial for refractory or relapsed follicular lymphoma and licensed to Taiho Pharmaceutical Co. Ltd in select Asian territories. Additionally, a compound from MethylGene's HDAC platform, EVP-0334, aimed at enhancing cognition in neurodegenerative disorders, has completed Phase I trials with EnVivo Pharmaceuticals Inc. The company benefits from a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for ocular disease applications based on its proprietary kinase inhibitor chemistry. MethylGene received a $26.13M Venture Round investment on 21 November 2012 from OrbiMed, Tavistock Group, Baker Brothers Advisors LLC, and Tang Capital Management. With its diverse product pipeline and established partnerships, MethylGene is positioned to make significant contributions to the field of biopharmaceuticals.